Mayne Pharma Group Ltd
ASX:MYX

Watchlist Manager
Mayne Pharma Group Ltd Logo
Mayne Pharma Group Ltd
ASX:MYX
Watchlist
Price: 4.92 AUD 3.14% Market Closed
Market Cap: 418.6m AUD
Have any thoughts about
Mayne Pharma Group Ltd?
Write Note

P/E
Price to Earnings

-2.3
Current
-1.9
Median
21.9
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-2.3
=
Market Cap
399.7m AUD
/
Net Income
-174.2m AUD
All Countries
Close
Market Cap P/E
AU
Mayne Pharma Group Ltd
ASX:MYX
399.7m AUD -2.3
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 347 888.9
US
Eli Lilly and Co
NYSE:LLY
744.2B USD 88.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP -15 783.5
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 34.9
US
Johnson & Johnson
NYSE:JNJ
373.9B USD 25.5
US
Merck & Co Inc
NYSE:MRK
258.4B USD 21.3
CH
Roche Holding AG
SIX:ROG
200.6B CHF 17.4
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 31.8
CH
Novartis AG
SIX:NOVN
180.7B CHF 11.6
US
Pfizer Inc
NYSE:PFE
146.9B USD 34.5
Earnings Growth
AU
Mayne Pharma Group Ltd
ASX:MYX
Average P/E: 33.2
Negative Multiple: -2.3
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
88.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
34.9
86%
US
Johnson & Johnson
NYSE:JNJ
25.5
-22%
US
Merck & Co Inc
NYSE:MRK
21.3
7 321%
CH
Roche Holding AG
SIX:ROG
17.4
32%
UK
AstraZeneca PLC
LSE:AZN
31.8
177%
CH
Novartis AG
SIX:NOVN
11.6
21%
US
Pfizer Inc
NYSE:PFE
34.5
733%

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-21
2-Years Forward
P/E
-87.8
3-Years Forward
P/E
21

See Also

Discover More